Miguel, Juliana, et al. “Cost-Effectiveness of Erlotinib Compared to Gefitinib for NSCLC With EGFR Mutations at the Inca”. Jornal Brasileiro De Economia Da Saúde, vol. 12, no. 1, Apr. 2020, pp. 8-15, doi:10.21115/JBES.v12.n1.p8-15.